Genetic Technologies Strategic Restructure Driving USA Sales Growth

Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of$7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...